Prophase Labs Inc

Prophase Labs Inc (PRPH) Stock Analysis

$0.363

-0.069 (-18.97%)At close

Loading chart…
High
0.473
Open
0.464
VWAP
0.38
Vol
5.49M
Mkt Cap
81.47M
Low
0.300
Amount
2.08M
EV/EBITDA, TTM
0.00

ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.

Valuation Metrics

The current forward P/E ratio for Prophase Labs Inc (PRPH) is 0.00, compared to its 5-year average forward P/E of 4.37.

Forward P/E

Fair
5Y Average P/E
4.37
Current P/E
0.00
Overvalued
35.26
Undervalued
-26.51

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
1.69
Current EV/EBITDA
0.00
Overvalued
25.45
Undervalued
-22.07

Forward P/S

Undervalued
5Y Average P/S
1.76
Current P/S
0.05
Overvalued
3.15
Undervalued
0.37

Alphio AI Price Scenarios for PRPH

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PRPH

$0.33

Scenario price

B

Base

Base · 50%PRPH

$0.24

Scenario price

B

Bear

Bear · 25%PRPH

$0.13

Scenario price

Events Timeline

2026-03-17 (ET)

08:20:00

ProPhase Labs Updates on Crown Medical Collections Progress

2026-02-03 (ET)

07:10:00

ProPhase Labs Initiates Sale or Strategic Partnership for BE-Smart

2026-01-26 (ET)

07:10:00

ProPhase Labs Updates on COVID-19 Testing Receivables Progress

2025-12-19 (ET)

20:00:00

ProPhase Labs Trading Halted, News Pending

07:10:00

ProPhase Labs and ABL Sign LOI for Proposed Reverse Merger

News

PRPH FAQ — answered by Alphio AI

ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started